SFSusan Furness

Susan Furness

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susan Furness has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia

    by Zongdao Shi, Huixu Xie, Ping Wang, Qi Zhang, Yan Wu, E Chen, Linda Ng, Helen V Worthington, Ian Needleman, Susan Furness

    Background Ventilator‐associated pneumonia (VAP) is defined as pneumonia developing in persons who have received mechanical ventilation for at least 48 hours. VAP is a potentially serious complication in these patients who are already critically ill. Oral hygiene care (OHC), using either a mouthrinse, gel, toothbrush, or combination, together with aspiration of secretions may reduce the risk of VAP in these patients. Objectives To assess the effects of OHC on the incidence of VAP in critically ill patients receiving mechanical ventilation in intensive care units (ICUs) in hospitals. Search methods We searched the Cochrane Oral Health Group's Trials Register (to 14 January 2013), CENTRAL (The Cochrane Library 2012, Issue 12), MEDLINE (OVID) (1946 to 14 January 2013), EMBASE (OVID) (1980 to 14 January 2013), LILACS (BIREME) (1982 to 14 January 2013), CINAHL (EBSCO) (1980 to 14 January 2013), Chinese Biomedical Literature Database (1978 to 14 January 2013), China National Knowledge Infrastructure (1994 to 14 January 2013), Wan Fang Database (January 1984 to 14 January 2013), OpenGrey and ClinicalTrials.gov (to 14 January 2013). There were no restrictions regarding language or date of publication. Selection criteria We included randomised controlled trials (RCTs) evaluating the effects of OHC (mouthrinse, swab, toothbrush or combination) in critically ill patients receiving mechanical ventilation. Data collection and analysis Two review authors independently assessed all search results, extracted data and undertook risk of bias. We contacted study authors for additional information. Trials with similar interventions and outcomes were pooled reporting odds ratios (OR) for dichotomous outcomes and mean differences (MD) for continuous outcomes using random‐effects models unless there were fewer than four studies. Main results Thirty‐five RCTs (5374 participants) were included. Five trials (14%) were assessed at low risk of bias, 17 studies (49%) were at high risk of bias, and 13 studies (37%) were assessed at unclear risk of bias in at least one domain. There were four main comparisons: chlorhexidine (CHX mouthrinse or gel) versus placebo/usual care, toothbrushing versus no toothbrushing, powered versus manual toothbrushing and comparisons of oral care solutions. There is moderate quality evidence from 17 RCTs (2402 participants, two at high, 11 at unclear and four at low risk of bias) that CHX mouthrinse or gel, as part of OHC, compared to placebo or usual care is associated with a reduction in VAP (OR 0.60, 95% confidence intervals (CI) 0.47 to 0.77, P < 0.001, I2 = 21%). This is equivalent to a number needed to treat (NNT) of 15 (95% CI 10 to 34) indicating that for every 15 ventilated patients in intensive care receiving OHC including chlorhexidine, one outcome of VAP will be prevented. There is no evidence of a difference between CHX and placebo/usual care in the outcomes of mortality (OR 1.10, 95% CI 0.87 to 1.38, P = 0.44, I2 = 2%, 15 RCTs, moderate quality evidence), duration of mechanical ventilation (MD 0.09, 95% CI ‐0.84 to 1.01 days, P = 0.85, I2 = 24%, six RCTs, moderate quality evidence), or duration of ICU stay (MD 0.21, 95% CI ‐1.48 to 1.89 days, P = 0.81, I2 = 9%, six RCTs, moderate quality evidence). There was insufficient evidence to determine whether there is a difference between CHX and placebo/usual care in the outcomes of duration of use of systemic antibiotics, oral health indices, microbiological cultures, caregivers preferences or cost. Only three studies reported any adverse effects, and these were mild with similar frequency in CHX and control groups. From three trials of children aged from 0 to 15 years (342 participants, moderate quality evidence) there is no evidence of a difference between OHC with CHX and placebo for the outcomes of VAP (OR 1.07, 95% CI 0.65 to 1.77, P = 0.79, I2 = 0%), or mortality (OR 0.73, 95% CI 0.41 to 1.30, P = 0.28, I2 = 0%), and insufficient evidence to determine the effect on the outcomes of duration of ventilation, duration of ICU stay, use of systemic antibiotics, plaque index, microbiological cultures or adverse effects, in children. Based on four RCTs (828 participants, low quality evidence) there is no evidence of a difference between OHC including toothbrushing (± CHX) compared to OHC without toothbrushing (± CHX) for the outcome of VAP (OR 0.69, 95% CI 0.36 to 1.29, P = 0.24 , I2 = 64%) and no evidence of a difference for mortality (OR 0.85, 95% CI 0.62 to 1.16, P = 0.31, I2 = 0%, four RCTs, moderate quality evidence). There is insufficient evidence to determine whether there is a difference due to toothbrushing for the outcomes of duration of mechanical ventilation, duration of ICU stay, use of systemic antibiotics, oral health indices, microbiological cultures, adverse effects, caregivers preferences or cost. Only one trial compared use of a powered toothbrush with a manual toothbrush providing insufficient evidence to determine the effect on any of the outcomes of this review. A range of other oral care solutions were compared. There is some weak evidence that povidone iodine mouthrinse is more effective than saline in reducing VAP (OR 0.35, 95% CI 0.19 to 0.65, P = 0.0009, I2 = 53%) (two studies, 206 participants, high risk of bias). Due to the variation in comparisons and outcomes among the trials in this group there is insufficient evidence concerning the effects of other oral care solutions on the outcomes of this review. Authors' conclusions Effective OHC is important for ventilated patients in intensive care. OHC that includes either chlorhexidine mouthwash or gel is associated with a 40% reduction in the odds of developing ventilator‐associated pneumonia in critically ill adults. However, there is no evidence of a difference in the outcomes of mortality, duration of mechanical ventilation or duration of ICU stay. There is no evidence that OHC including both CHX and toothbrushing is different from OHC with CHX alone, and some weak evidence to suggest that povidone iodine mouthrinse is more effective than saline in reducing VAP. There is insufficient evidence to determine whether powered toothbrushing or other oral care solutions are effective in reducing VAP.


  • Hormone therapy in postmenopausal women and risk of endometrial hyperplasia

    by Susan Furness, Helen Roberts, Jane Marjoribanks, Anne Lethaby

    Reduced circulating estrogen levels around the time of the menopause can induce unacceptable symptoms that affect the health and well-being of women. Hormone therapy (both unopposed estrogen and estrogen/progestogen combinations) is an effective treatment for these symptoms, but is associated with risk of harms. Guidelines recommend that hormone therapy be given at the lowest effective dose and treatment should be reviewed regularly. The aim of this review is to identify the minimum dose(s) of progestogen required to be added to estrogen so that the rate of endometrial hyperplasia is not increased compared to placebo. The objective of this review is to assess which hormone therapy regimens provide effective protection against the development of endometrial hyperplasia or carcinoma. We searched the Cochrane Menstrual Disorders and Subfertility Group trials register (searched January 2012), The Cochrane Library (Issue 1, 2012), MEDLINE (1966 to January 2012), EMBASE (1980 to January 2012), Current Contents (1993 to May 2008), Biological Abstracts (1969 to 2008), Social Sciences Index (1980 to May 2008), PsycINFO (1972 to January 2012) and CINAHL (1982 to May 2008). Attempts were made to identify trials from citation lists of reviews and studies retrieved, and drug companies were contacted for unpublished data. Randomised comparisons of unopposed estrogen therapy, combined continuous estrogen-progestogen therapy, sequential estrogen-progestogen therapy with each other or placebo, administered over a minimum period of 12 months. Incidence of endometrial hyperplasia/carcinoma assessed by a biopsy at the end of treatment was a required outcome. Data on adherence to therapy, rates of additional interventions, and withdrawals owing to adverse events were also extracted. In this update, 46 studies were included. Odds ratios (ORs) were calculated for dichotomous outcomes. The small numbers of studies in each comparison and the clinical heterogeneity precluded meta-analysis for many outcomes. Unopposed estrogen is associated with increased risk of endometrial hyperplasia at all doses, and durations of therapy between one and three years. For women with a uterus the risk of endometrial hyperplasia with hormone therapy comprising low-dose estrogen continuously combined with a minimum of 1 mg norethisterone acetate (NETA) or 1.5 mg medroxyprogesterone acetate (MPA) is not significantly different from placebo at two years (1 mg NETA: OR 0.04; 95% confidence interval (CI) 0 to 2.8; 1.5 mg MPA: no hyperplasia events). Hormone therapy for postmenopausal women with an intact uterus should comprise both estrogen and progestogen to reduce the risk of endometrial hyperplasia. Traitement hormonal des femmes post-ménopausées et risques d'hyperplasie endométriale. Une diminution des niveaux d'œstrogène dans l'organisme aux alentours de la ménopause peut provoquer des symptômes inacceptables affectant la santé et le bien-être des femmes. Un traitement hormonal (combinaisons d'œstrogène non compensé et d'œstrogène/progestatif) est efficace contre ces symptômes, mais il présente des risques. Des recommandations préconisent qu'un traitement hormonal doit être administré à une dose efficace minimale et faire l'objet d'un contrôle régulier. L'objectif de la présente revue consiste à identifier la ou les doses minimales de progestatif devant être ajoutées à l'œstrogène de sorte que les taux d'hyperplasie endométriale n'augmentent pas par rapport à un placebo. L'objectif de la présente revue consiste à évaluer la posologie de traitement hormonal qui assure une protection efficace contre le développement de l'hyperplasie ou du carcinome endométrial(e). Nous avons effectué des recherches dans le registre des essais cliniques du groupe Cochrane sur les troubles menstruels et de la fertilité (recherches effectuées en janvier 2012), The Cochrane Library (numéro 1, 2012), MEDLINE (de 1966 à janvier 2012), EMBASE (de 1980 à janvier 2012), Current Contents (de 1993 à mai 2008), Biological Abstracts (de 1969 à 2008), Social Sciences Index (de 1980 à mai 2008), PsycINFO (de 1972 à janvier 2012) et CINAHL (de 1982 à mai 2008). Des tentatives ont été entreprises afin d'identifier des essais dans des bibliographies des revues et des études extraites. Des laboratoires pharmaceutiques ont également été contactés afin d'obtenir des données non publiées. Des comparaisons randomisées d'un traitement par œstrogène non compensé, d'un traitement par œstrogène/progestatif continu combiné, d'un traitement par œstrogène/progestatif séquentiel les uns par rapport aux autres ou par rapport à un placebo, administrés pendant une période minimale de 12 mois. L'incidence de l'hyperplasie/carcinome endométrial(e) évalué(e) par une biopsie à la fin du traitement constituait un critère de jugement obligatoire. Les données relatives à l'observance thérapeutique, les taux d'interventions supplémentaires et les arrêts prématurés dus à des événements indésirables ont également été extraits. Au total, 46 études ont été incluses dans cette mise à jour. Des odds ratios (OR) ont été calculés pour les résultats dichotomiques. Le nombre réduit d'études dans chaque comparaison et l'hétérogénéité clinique ont empêché la réalisation d'une méta-analyse pour de nombreux critères. L'œstrogène non compensé est lié à des risques accrus d'hyperplasie endométriale quelles que soient les doses, ainsi qu'à des durées de traitement comprises entre un et trois ans. Chez les femmes ayant un utérus, les risques d'hyperplasie endométriale dus à un traitement hormonal composé d'œstrogène à faibles doses combiné en continu à 1 mg d'acétate de noréthistérone (NETA) ou 1,5 mg d'acétate de médroxyprogestérone (MPA) au minimum ne sont pas significativement différents d'un placebo au bout de deux ans (1 mg NETA : OR 0,04 ; intervalle de confiance (IC) à 95 % 0 à 2,8 ; 1,5 mg MPA : aucun événement d'hyperplasie). Un traitement hormonal destiné à des femmes post-ménopausées dont l'utérus est intact doit contenir de l'œstrogène et un progestatif afin de réduire les risques d'hyperplasie endométriale. 閉経後女性でのホルモン療法および子宮内膜増殖症リスク 閉経前後での循環エストロゲン値低下により、女性の健康と福祉に影響する受け入れがたい症状が起こる。ホルモン療法(拮抗されていないエストロゲンとエストロゲン/プロゲストゲン併用の両方)は、これらの症状に対する有効な治療であるが、有害性リスクを伴っている。ガイドラインでは、ホルモン療法を最小有効量で投与し、定期的に治療を見直すよう推奨している。本レビューの目的は、プラセボに比べて子宮内膜増殖症の発症率が上昇しないよう、エストロゲンに追加すべきプロゲストゲンの最小投与量を同定することである。 本レビューの目的は、どのホルモン療法レジメンにより子宮内膜増殖症または子宮内膜癌の発症予防に有効性を認めるか評価することである。 Cochrane Menstrual Disorders and Subfertility Group trials register(2012年1月検索)、コクラン・ライブラリ(2012年第1号)、MEDLINE(1966~2012年1月)、EMBASE(1980~2012年1月)、Current Contents(1993~2008年5月)、Biological Abstracts(1969~2008年)、Social Sciences Index(1980~2008年5月)、PsycINFO(1972~2012年1月)、CINAHL(1982~2008年5月)を検索した。 回収したレビューおよび研究の引用リストから試験の同定を試み、製薬会社に未発表データについて連絡を取った。 最低12ヵ月以上投与された、拮抗されないエストロゲン療法、持続的エストロゲン-プロゲストゲン併用療法、逐次的エストロゲン-プロゲストゲン療法とそれぞれまたはプラセボとの比較を行っているランダム化比較。投与終了時の生検により評価した子宮内膜増殖症/子宮内膜癌の罹患率を必須のアウトカムとした。治療遵守、追加介入率、有害事象による投与中止に関するデータも抽出した。 本更新において46件の研究を組み入れた。オッズ比(OR)を二値アウトカムについて算出した。各比較での研究数の少なさ、および臨床的異質性のため、多数のアウトカムのメタアナリシスが妨げられた。 拮抗されないエストロゲンは、全用量と1~3年の投与期間で子宮内膜増殖症リスクの上昇に関連していた。子宮のある女性では、低用量エストロゲンと最低1 mgの酢酸ノルエチステロン(NETA)または1.5 mgの酢酸メドロキシプロゲステロン(MPA)との持続併用からなるホルモン療法による子宮内膜増殖症リスクは、2年の時点でプラセボと有意差はなかった[1 mg NETA、OR 0.04、95%信頼区間(CI)0~2.8;1.5 mg MPA、子宮内膜増殖症イベントなし]。 無傷の子宮を有する閉経後女性に対するホルモン療法は、子宮内膜増殖症リスクの低下のため、エストロゲンとプロゲストゲンの両方から構成されるべきである。 Terapia hormonal em mulheres na posmenopausa e risco de hiperplasia endomentrial Redução nos níveis de estrógeno circulante na peri-menopausa podem induzir sintomas inaceitáveis que afetam a saúde e o bem estar da mulher. Terapia de reposição hormonal (estrogênio isolado ou estrogênio combinado com o progestagênio) é um tratamento eficaz para esses sintomas, mas é associado a riscos de danos. Diretrizes recomendam que a terapia hormonal seja oferecida na menor dose eficaz e o tratamento deve ser revisado regularmente. O objetivo desta revisão é identificar a dose mínima(s) requerida de progestagênio a ser adicionada ao estrogênio para que a taxa de hiperplasia endometrial não seja superior a do placebo. O objetivo desta revisão é avaliar quais os esquemas de terapia hormonal proporcionam proteção eficaz contra o desenvolvimento de hiperplasia endometrial ou carcinoma. Pesquisamos em Cochrane Menstrual Disorders and Subfertility Group trials register (pesquisado em Janeiro de 2012), The Cochrane Library (Volume 1, 2012), MEDLINE (1966 até Janeiro de 2012), EMBASE (1980 até Janeiro de 2012), Current Contents (1993 até Maio de 2008), Biological Abstracts (1969 até 2008), Social Sciences Index (1980 até Maio de 2008), PsycINFO (1972 até Janeiro de 2012) and CINAHL (1982 até Maio de 2008). Foram feitas tentativas de identificar os ensaios a partir de listas de citações de avaliações e estudos recuperados, e as companhias farmacêuticas foram contatadas para dados não publicados. Comparações randomizadas de terapia com estrogênio isolado, combinação contínua de estrogênio-progestagênio, terapia estrogênio-progestagênio sequencial, entre si ou placebo, administrada por um período mínimo de 12 meses. A incidência de hiperplasia endometrial/ carcinoma avaliado por biópsia ao final do tratamento foi o principal desfecho. Dados sobre a adesão à terapia, taxas de intervenções adicionais, e as desistências devido aos eventos adversos também foram extraídos. Nessa atualização, 46 estudos foram incluídos. Odds Ratio (OR) foram calculados para desfechos dicotômicos. O pequeno número de estudos em cada comparação e a heterogeneidade clínica impossibilitaram a realização de meta-análises de muitos desfechos. Estrogênio isolado está associado a um risco aumentado de hiperplasia endometrial em todas as doses e duração da terapia entre um e três anos. Para as mulheres com o útero, o risco de hiperplasia endometrial com terapia hormonal continua com baixa dose de estrogênio combinado com no mínimo 1mg de acetato de noretisterona (NETA) ou 1,5mg de acetato de medroxiprogesterona (MPA), não é significativamente diferente do placebo por 2 anos (1mg NETA: OR 0,04; IC 95% 0 a 2,8; 1,5mg MPA: nenhum evento de hiperplasia). Terapia hormonal para mulheres na pós-menopausa com útero intacto deve compreender ambos estrogênio e progestagênio para reduzir o risco de hiperplasia endometrial.


  • Interventions for the management of dry mouth: topical therapies

    by Susan Furness, Helen V Worthington, Gemma Bryan, Sarah Birchenough, Roddy McMillan

    Background Xerostomia (the feeling of dry mouth) is a common symptom especially in older adults. Causes of dry mouth include medications, autoimmune disease (Sjögren's Syndrome), radiotherapy or chemotherapy for cancer, hormone disorders and infections. Objectives To determine which topical treatments for dry mouth are effective in reducing this symptom. Search methods We searched the following electronic databases: the Cochrane Oral Health Group Trials Register (28 October 2011), The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 4 2011), MEDLINE via OVID (1950 to 28 October 2011), EMBASE via OVID (1980 to 28 October 2011), CINAHL via EBSCO (1980 to 28 October 2011), AMED via OVID (1985 to 28 October 2011), CANCERLIT via PubMed (1950 to 28 October 2011). Selection criteria We included randomised controlled trials of topical interventions such as lozenges, sprays, mouthrinses, gels, oils, chewing gum or toothpastes for the treatment of dry mouth symptom. We classified interventions into two broad categories, saliva stimulants and saliva substitutes, and these were compared with either placebo or another intervention. We included both parallel group and crossover trials. Data collection and analysis Two or more review authors independently carried out data extraction and assessed risk of bias. Trial authors were contacted for additional information as required. Main results Thirty‐six randomised controlled trials involving 1597 participants met the inclusion criteria. Two trials compared saliva stimulants to placebo, nine trials compared saliva substitutes to placebo, five trials compared saliva stimulants directly with saliva substitutes, 18 trials directly compared two or more saliva substitutes, and two trials directly compared two or more saliva stimulants. Only one trial was at low risk of bias and 17 were at high risk of bias. Due to the range of interventions, comparisons and outcome measures in the trials, meta‐analysis was possible for only a few comparisons. Oxygenated glycerol triester (OGT) saliva substitute spray shows evidence of effectiveness compared to an electrolyte spray (standardised mean difference (SMD) 0.77, 95% confidence interval (CI) 0.38 to 1.15) which corresponds to approximately a mean difference of 2 points on a 10‐point visual analogue scale (VAS) for mouth dryness. Both integrated mouthcare systems (toothpaste + gel + mouthwash) and oral reservoir devices show promising results but there is insufficient evidence at present to recommend their use. Although chewing gum is associated with increased saliva production in the majority of those with residual capacity, there is no evidence that gum is more or less effective than saliva substitutes. Authors' conclusions There is no strong evidence from this review that any topical therapy is effective for relieving the symptom of dry mouth. OGT spray is more effective than an aqueous electrolyte spray (SMD 0.77, 95% CI 0.38 to 1.15) which is approximately equivalent to a mean difference of 2 points on a 10‐point VAS scale for mouth dryness. Chewing gums appear to increase saliva production in those with residual secretory capacity and may be preferred by patients, but there is no evidence that gum is better or worse than saliva substitutes. Integrated mouthcare systems and oral reservoir devices may be helpful but further research is required to confirm this. Well designed, adequately powered randomised controlled trials of topical interventions for dry mouth, which are designed and reported according to CONSORT guidelines, are required to provide evidence to guide clinical care. For many people the symptom of dry mouth is a chronic problem and trials should evaluate whether treatments are palatable, effective in reducing xerostomia, as well as the long‐term effects of treatments on quality of life of those with chronic dry mouth symptoms.


  • Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy

    by Susan Furness, Anne-Marie Glenny, Helen V Worthington, Sue Pavitt, Richard Oliver, Jan E Clarkson, Michaelina Macluskey, Kelvin Kw Chan, David I Conway

    Oral cavity and oropharyngeal cancers are frequently described as part of a group of oral cancers or head and neck cancer. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely to be advanced at the time of diagnosis, are managed with radiotherapy or chemoradiation. Surgery for oral cancers can be disfiguring and both surgery and radiotherapy have significant functional side effects, notably impaired ability to eat, drink and talk. The development of new chemotherapy agents, new combinations of agents and changes in the relative timing of surgery, radiotherapy, and chemotherapy treatments may potentially bring about increases in both survival and quality of life for this group of patients. To determine whether chemotherapy, in addition to radiotherapy and/or surgery for oral cavity and oropharyngeal cancer results in improved survival, disease free survival, progression free survival, locoregional control and reduced recurrence of disease. To determine which regimen and time of administration (induction, concomitant or adjuvant) is associated with better outcomes. Electronic searches of the Cochrane Oral Health Group's Trials Register, CENTRAL, MEDLINE, EMBASE, AMED were undertaken on 1st December 2010. Reference lists of recent reviews and included studies were also searched to identify further trials. Randomised controlled trials where more than 50% of participants had primary tumours in the oral cavity or oropharynx, and which compared the addition of chemotherapy to other treatments such as radiotherapy and/or surgery, or compared two or more chemotherapy regimens or modes of administration, were included. Eighty-nine trials which met the inclusion criteria were assessed for risk of bias and data were extracted by two or more review authors. The primary outcome was total mortality. Trial authors were contacted for additional information or for clarification. There is evidence of a small increase in overall survival associated with induction chemotherapy compared to locoregional treatment alone (25 trials), hazard ratio (HR) of mortality 0.92 (95% confidence interval (CI) 0.84 to 1.00, P = 0.06). Post-surgery adjuvant chemotherapy is associated with improved overall survival compared to surgery ± radiotherapy alone (10 trials), HR of mortality 0.88 (95% CI 0.79 to 0.99, P = 0.03), and there is some evidence that this improvement may be greater with concomitant adjuvant chemoradiotherapy (4 trials), HR of mortality 0.84 (95% CI 0.72 to 0.98, P = 0.03). In patients with unresectable tumours, there is evidence that concomitant or alternating chemoradiotherapy is associated with improved survival compared to radiotherapy alone (26 trials), HR of mortality 0.78 (95% CI 0.73 to 0.83, P < 0.00001). These findings are confirmed by sensitivity analyses based on studies assessed at low risk of bias. There is insufficient evidence to identify which agent(s) and/or regimen(s) are the most effective. The additional toxicity attributable to chemotherapy in the combined regimens remains unquantified. Chemotherapy, in addition to radiotherapy and surgery, is associated with improved overall survival in patients with oral cavity and oropharyngeal cancers. Induction chemotherapy may prolong survival by 8 to 20% and adjuvant concomitant chemoradiotherapy may prolong survival by up to 16%. In patients with unresectable tumours, concomitant or alternating chemoradiotherapy may prolong survival by 10 to 22%. There is insufficient evidence as to which agent or regimen is most effective and the additional toxicity associated with chemotherapy given in addition to radiotherapy and/or surgery cannot be quantified. Intervenciones para el tratamiento del cáncer bucal y orofaríngeo: quimioterapia El cáncer bucal y orofaríngeo se describe con frecuencia como parte de un grupo de cánceres de la cavidad bucal o cáncer de cabeza y cuello. El tratamiento del cáncer bucal en general es la cirugía seguida de radioterapia, mientras que los cánceres orofaríngeos, que tienen mayor probabilidad de encontrarse en un estadio avanzado en el momento del diagnóstico, se tratan con radioterapia o quimiorradiación. La cirugía para el cáncer de la cavidad bucal puede dejar secuelas deformantes y tanto la cirugía como la radioterapia tienen efectos secundarios funcionales significativos, especialmente en lo que concierne a la capacidad para comer, beber y hablar. El desarrollo de agentes de quimioterapia nuevos, combinaciones nuevas de agentes y los cambios en el momento relativo de la cirugía, radioterapia y quimioterapia, pueden dar lugar a aumentos potenciales tanto en la supervivencia como en la calidad de vida para este grupo de pacientes. Determinar si la quimioterapia, como agregado a la radioterapia y la cirugía para el cáncer bucal y orofaríngeo mejora la supervivencia, la supervivencia libre de enfermedad, la supervivencia libre de progresión, el control locorregional y reduce la recidiva de la enfermedad. Determinar qué régimen y momento de administración (de inducción, concomitante o adjuvante) se asocia con mejores resultados. Se hicieron búsquedas en el Registro de Ensayos del Grupo Cochrane de Salud Oral (Cochrane Oral Health Group), CENTRAL, MEDLINE EMBASE y AMED hasta el 1 de diciembre 2010. También se realizaron búsquedas en las listas de referencias de revisiones recientes y de los estudios incluidos para identificar ensayos adicionales. Se incluyeron los ensayos controlados aleatorios donde más del 50% de los participantes tuviese tumores primarios en la cavidad bucal o la orofaringe, y que compararan el agregado de quimioterapia a otros tratamientos como la radioterapia y la cirugía, o que compararan dos o más regímenes de quimioterapia o modalidades de administración. Ochenta y nueve ensayos que cumplieron con los criterios de inclusión fueron evaluados en cuanto al riesgo de sesgo, y...


  • Interventions for the management of dry mouth: non-systemic therapies

    by Susan Furness, Helen V Worthington, Gemma Bryan, Sarah Birchenough, Roddy McMillan


  • Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy

    by Susan Furness, Anne-Marie Glenny, Helen V Worthington, Sue Pavitt, Richard Oliver, Jan E Clarkson, Michaelina Macluskey, Kelvin Kw Chan, David I Conway, The Csroc Expert Panel

    Oral cavity and oropharyngeal cancers are frequently described as part of a group of oral cancers or head and neck cancer. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely to be advanced at the time of diagnosis, are managed with radiotherapy or chemoradiation. Surgery for oral cancers can be disfiguring and both surgery and radiotherapy have significant functional side effects, notably impaired ability to eat, drink and talk. The development of new chemotherapy agents, new combinations of agents and changes in the relative timing of surgery, radiotherapy, and chemotherapy treatments may potentially bring about increases in both survival and quality of life for this group of patients. To determine whether chemotherapy, in addition to radiotherapy and/or surgery for oral cavity and oropharyngeal cancer results in improved survival, disease free survival, progression free survival, locoregional control and reduced recurrence of disease. To determine which regimen and time of administration (induction, concomitant or adjuvant) is associated with better outcomes. Electronic searches of the Cochrane Oral Health Group's Trials Register, CENTRAL, MEDLINE, EMBASE, AMED were undertaken on 28th July 2010. Reference lists of recent reviews and included studies were also searched to identify further trials. Randomised controlled trials where more than 50% of participants had primary tumours in the oral cavity or oropharynx, and which compared the addition of chemotherapy to other treatments such as radiotherapy and/or surgery, or compared two or more chemotherapy regimens or modes of administration, were included. Trials which met the inclusion criteria were assessed for risk of bias using six domains: sequence generation, allocation concealment, blinding, completeness of outcome data, selective reporting and other possible sources of bias. Data were extracted using a specially designed form and entered into the characteristics of included studies table and the analysis sections of the review. The proportion of participants in each trial with oral cavity and oropharyngeal cancers are recorded in Additional Table 1. There was no statistically significant improvement in overall survival associated with induction chemotherapy compared to locoregional treatment alone in 25 trials (hazard ratio (HR) of mortality 0.92, 95% confidence interval (CI) 0.84 to 1.00). Post-surgery adjuvant chemotherapy was associated with improved overall survival compared to surgery ± radiotherapy alone in 10 trials (HR of mortality 0.88, 95% CI 0.79 to 0.99), and there was an additional benefit of adjuvant concomitant chemoradiotherapy compared to radiotherapy in 4 of these trials (HR of mortality 0.84, 95% CI 0.72 to 0.98). Concomitant chemoradiotherapy resulted in improved survival compared to radiotherapy alone in patients whose tumours were considered unresectable in 25 trials (HR of mortality 0.79, 95% CI 0.74 to 0.84). However, the additional toxicity attributable to chemotherapy in the combined regimens remains unquantified. Chemotherapy, in addition to radiotherapy and surgery, is associated with improved overall survival in patients with oral cavity and oropharyngeal cancers. Induction chemotherapy is associated with a 9% increase in survival and adjuvant concomitant chemoradiotherapy is associated with a 16% increase in overall survival following surgery. In patients with unresectable tumours, concomitant chemoradiotherapy showed a 22% benefit in overall survival compared with radiotherapy alone.


  • Pre and post-operative medical therapy for endometriosis surgery

    by Susan Furness, Christine Yap, Cindy Farquhar, Ying C Cheong

    Background Endometriosis is a common gynaecological condition affecting approximately 10% of women of reproductive age (Ozkan 2008). Common symptoms are dysmenorrhoea, pelvic pain, infertility or a pelvic mass. Diagnosis by laparoscopy or laparotomy enables identification of the location, extent and severity of the disease. Surgery may include removal (excision) or destruction (ablation) of endometriotic tissue, division of adhesions and removal of endometriotic cysts. Laparoscopic excision or ablation of endometriosis has been shown to be effective in the management of pain in mild to moderate endometriosis. Adjunctive medical treatment pre or post‐operatively may prolong the symptom‐free interval. Objectives To determine the effectiveness of medical therapies for hormonal suppression before or after surgery for endometriosis for improving painful symptoms, reducing disease recurrence and increasing pregnancy rates. Search methods We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register (searched Sept 2010), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Sept 2010), MEDLINE (January 1966 to September 2010), EMBASE (January 1985 to September 2010) and reference lists of articles. Selection criteria Trials were included if they were randomised controlled trials comparing medical therapies for hormonal suppression before or after or before and after, surgery for endometriosis. Data collection and analysis Data extraction and assessment of risk of bias were performed independently by two authors. Where possible, data were combined using relative risk (RR), standardised mean difference or mean difference and 95% confidence intervals (CI). Main results Sixteen trials were included. Two trials of pre‐surgical medical therapy showed no evidence of benefit compared to surgery alone. There was no evidence of benefit for post‐surgical hormonal suppression of endometriosis compared to surgery alone for the outcomes of pain, disease recurrence or pregnancy rates (RR 0.84, 95% CI 0.59 to 1.18). There were no trials identified in the search that compared hormonal suppression of endometriosis before and after surgery with surgery alone. One trial found no evidence that pre‐surgical hormonal suppression was different from post‐surgical hormonal suppression for the outcome of pain. Another single trial comparing post‐surgical medical therapy with both pre and post‐surgery found no difference in the outcomes of American Fertility Society (AFS) scores and pregnancy rate. Authors' conclusions There is no evidence of benefit associated with post surgical medical therapy and insufficient evidence to determine whether there is a benefit from pre‐surgical medical therapy with regard to the outcomes evaluated.


  • A systematic review of transvaginal ultrasonography, sonohysterography and hysteroscopy for the investigation of abnormal uterine bleeding in premenopausal women

    by Cynthia Farquhar, Alec Ekeroma, Susan Furness, Bruce Arroll

    Background. To determine the accuracy of transvaginal ultrasonography, sonohysterography and diagnostic hysteroscopy for the investigation of abnormal uterine bleeding in premenopausal women. Design. Systematic review of common diagnostic imaging tests. Data sources. Relevant papers were identified through electronic searching of MEDLINE (1980 to July 2001) and EMBASE (1980 to July 2001) and manual searching of a bibliography of primary and review articles. Review methods. Studies were selected if accuracy of transvaginal ultrasonography, sonohysterography and diagnostic hysteroscopy was compared with a reference standard and included data that could be abstracted into a two‐by‐two table in order to calculate sensitivity and specificity. Quality assessment and data extraction were performed by at least two independent reviewers. Diagnostic accuracy was determined by calculating positive and negative likelihood ratios for all intrauterine pathologies, submucous fibroids and endometrial hyperplasia. Results. Nineteen studies met the inclusion criteria. Statistically significant heterogenenity was present between the likelihood ratios for studies of transvaginal ultrasound. A positive test result with sonohysterography diagnosed submucous fibroids with a pooled likelihood ratio of 29.7 (17.8, 49.6). A positive test result with hysteroscopy diagnosed submucous fibroids with a pooled likelihood ratio of 29.4 (13.4, 65.3), and any intrauterine pathology with a pooled likelihood ratio of 7.7 (4.3, 13.7). A negative test result with hysteroscopy for diagnosing any intrauterine pathology had a pooled likelihood ratio of 0.07 (0.04, 0.15). Conclusion. Although there was considerable variability present between the studies, all three diagnostic tests were moderately accurate in detecting intrauterine pathology. However, sonohysterography and hysteroscopy performed better than transvaginal ultrasound in detecting submucous fibroids.